Source:http://linkedlifedata.com/resource/pubmed/id/19798106
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2010-2-15
|
pubmed:abstractText |
In many tumor cell types, ionizing radiation or DNA-damaging anticancer drugs enhance sensitivity to death receptor-mediated apoptosis, which is of clinical interest. APO010, a form of CD95/Fas ligand is currently in a phase I trial in patients with solid tumors. To analyze the potential of combined modality treatment with APO010, we used p53-mutant Jurkat T leukemic cells, in which the mitochondrial pathway was blocked by Bcl-2 overexpression. These cells were strongly sensitized to APO010 by pretreatment with ionizing - or UV radiation, etoposide, histone deacetylase - or proteasome inhibitors. These stimuli alone did not induce apoptosis in J16-Bcl-2 cells. Sensitization could not be explained by the overruling of mitochondrial resistance imposed by Bcl-2, upregulation of CD95 membrane levels or modulation of inhibitor of apoptosis proteins. Rather, the stimuli commonly downregulated c-FLIP(L/S) protein levels, which was causally related to the sensitization: deliberate c-FLIP(L/S) downregulation by RNA interference largely overruled the capacity of the various stimuli to sensitize Jurkat-Bcl-2 cells to apoptotic execution by APO010. In p53-mutant, Bcl-2 overexpressing HCT-15 colon carcinoma cells, c-FLIP downregulation correlated with sensitization to APO010 for some, but not all stimuli. We conclude that c-FLIP downregulation represents a mechanism by which diverse anticancer regimens can facilitate tumor cell execution by CD95/Fas through the direct pathway of caspase activation.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, Phytogenic,
http://linkedlifedata.com/resource/pubmed/chemical/CASP8 and FADD-Like Apoptosis...,
http://linkedlifedata.com/resource/pubmed/chemical/Etoposide,
http://linkedlifedata.com/resource/pubmed/chemical/Fas Ligand Protein,
http://linkedlifedata.com/resource/pubmed/chemical/JNK Mitogen-Activated Protein...,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-bcl-2
|
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
1476-5403
|
pubmed:author | |
pubmed:issnType |
Electronic
|
pubmed:volume |
17
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
551-61
|
pubmed:meshHeading |
pubmed-meshheading:19798106-Antineoplastic Agents,
pubmed-meshheading:19798106-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:19798106-Apoptosis,
pubmed-meshheading:19798106-CASP8 and FADD-Like Apoptosis Regulating Protein,
pubmed-meshheading:19798106-Cell Line, Tumor,
pubmed-meshheading:19798106-Clinical Trials, Phase I as Topic,
pubmed-meshheading:19798106-Down-Regulation,
pubmed-meshheading:19798106-Etoposide,
pubmed-meshheading:19798106-Fas Ligand Protein,
pubmed-meshheading:19798106-Humans,
pubmed-meshheading:19798106-JNK Mitogen-Activated Protein Kinases,
pubmed-meshheading:19798106-Mitochondria,
pubmed-meshheading:19798106-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:19798106-RNA Interference
|
pubmed:year |
2010
|
pubmed:articleTitle |
Radiation and anticancer drugs can facilitate mitochondrial bypass by CD95/Fas via c-FLIP downregulation.
|
pubmed:affiliation |
Division of Immunology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|